Ginkgo Bioworks Holdings Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GINKGO BIOWORKS HOLDINGS, INC. | ||
| Date: February 25, 2025 | By: | /s/ Jason Kelly |
|---|---|---|
| Jason Kelly | ||
| Chief Executive Officer | ||
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Jason Kelly | Chief Executive Officer and Director | February 25, 2025 |
| Jason Kelly | (Principal Executive Officer) | |
| /s/ Mark Dmytruk | Chief Financial Officer | February 25, 2025 |
| Mark Dmytruk | (Principal Financial Officer) | |
| /s/ Steven Coen | Chief Accounting Officer | February 25, 2025 |
| Steven Coen | (Principal Accounting Officer) | |
| /s/ Shyam Sankar | Director, Chair of the Board | February 25, 2025 |
| Shyam Sankar | ||
| /s/ Ross Fubini | Director | February 25, 2025 |
| Ross Fubini | ||
| /s/ Kathy Hopinkah Hannan | Director | February 25, 2025 |
| Kathy Hopinkah Hannan | ||
| /s/ Christian Henry | Director | February 25, 2025 |
| Christian Henry | ||
| /s/ Sri Kosuri | Director | February 25, 2025 |
| Sri Kosuri | ||
| /s/ Myrtle Potter | Director | February 25, 2025 |
| Myrtle Potter | ||
| /s/ Reshma Shetty | President, Chief Operating Officer and Director | February 25, 2025 |
| Reshma Shetty | ||
| /s/ Harry E. Sloan | Director | February 25, 2025 |
| Harry E. Sloan | ||
GINKGO BIOWORKS HOLDINGS, INC.
Index to Consolidated Financial Statements as of December 31, 2024 and 2023 and for the Years Ended December 31, 2024, 2023 and 2022
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 34) | F-2 |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | F-5 |
| Consolidated Balance Sheets | F-6 |
| Consolidated Statements of Operations and Comprehensive Loss | F-7 |
| Consolidated Statements of Stockholders’ Equity | F-9 |
| Consolidated Statements of Cash Flows | F-11 |
| Notes to Consolidated Financial Statements | F-13 |
| 1. Organization and Basis of Presentation | F-13 |
| 2. Summary of Significant Accounting Policies | F-13 |
| 3. Restructuring | F-23 |
| 4. Acquisitions and Divestitures | F-24 |
| 5. Fair Value Measurements | F-33 |
| 6. Investments and Equity Method Investments | F-37 |
| 7. Variable Interest Entities | F-39 |
| 8. Goodwill and Intangible Assets, net | F-40 |
| 9. Leases | F-41 |
| 10. Supplemental Financial Information | F-44 |
| 11. Commitments and Contingencies | F-46 |
| 12. Stockholders' Equity | F-47 |
| 13. Stock-Based Compensation | F-48 |
| 14. Revenue Recognition | F-52 |
| 15. Segment Information | F-53 |
| 16. Significant Collaborations Transactions with Related Parties | F-55 |
| 17. Employee Benefit Plan | F-64 |
| 18. Income Taxes | F-64 |
| 19. Net Loss per Share | F-67 |
| 20. Related Parties | F-68 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.